Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)
(Delayed Data from NSDQ)
$0.96 USD
0.00 (0.47%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.95 -0.01 (-1.49%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BDRX 0.96 0.00(0.47%)
Will BDRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BDRX
Biodexa Pharmaceuticals Unveils Series G Warrant
12 Health Care Stocks Moving In Tuesday's After-Market Session
DQ, BNED and BDRX among pre-market losers
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
GWAV and BRSH among mid-day movers